NASDAQ:KOOL - Cesca Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.53 +0.03 (+6.00 %)
(As of 05/22/2018 03:25 PM ET)
Previous Close$0.51
Today's Range$0.50 - $0.55
52-Week Range$0.50 - $6.44
Volume8,958 shs
Average Volume615,025 shs
Market Capitalization$5.97 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.73

About Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics logoCesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments. The Clinical Development Division segment involves in developing autologous stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology, and orthopedic markets. The Device Division segment includes development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

Receive KOOL News and Ratings via Email

Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100

Debt

Debt-to-Equity Ratio0.23
Current Ratio1.61
Quick Ratio0.79

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.52 million
Price / Sales0.42
Cash Flow$0.2190 per share
Price / Cash2.42
Book Value$3.11 per share
Price / Book0.17

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-29,090,000.00
Net Margins-56.21%
Return on Equity-20.31%
Return on Assets-12.98%

Miscellaneous

Employees70
Outstanding Shares11,480,000

Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) issued its quarterly earnings results on Thursday, March, 22nd. The biotechnology company reported $0.01 EPS for the quarter. The biotechnology company had revenue of $2.94 million for the quarter. Cesca Therapeutics had a negative return on equity of 20.31% and a negative net margin of 56.21%. View Cesca Therapeutics' Earnings History.

When is Cesca Therapeutics' next earnings date?

Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, September, 18th 2018. View Earnings Estimates for Cesca Therapeutics.

Who are some of Cesca Therapeutics' key competitors?

Who are Cesca Therapeutics' key executives?

Cesca Therapeutics' management team includes the folowing people:
  • Xiao Chun Xu, Chairman, President & Chief Executive Officer
  • Vivian H. Liu, Chief Operating Officer & Director
  • Jeffery Cauble, Principal Financial & Accounting Officer
  • Philip H. Coelho, Chief Technology Officer
  • Dalip Sethi, Senior Director-Research & Development

Has Cesca Therapeutics been receiving favorable news coverage?

Media stories about KOOL stock have trended somewhat negative recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cesca Therapeutics earned a news sentiment score of 0.00 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Cesca Therapeutics?

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cesca Therapeutics' stock price today?

One share of KOOL stock can currently be purchased for approximately $0.53.

How big of a company is Cesca Therapeutics?

Cesca Therapeutics has a market capitalization of $5.97 million and generates $14.52 million in revenue each year. Cesca Therapeutics employs 70 workers across the globe.

How can I contact Cesca Therapeutics?

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]


MarketBeat Community Rating for Cesca Therapeutics (KOOL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cesca Therapeutics (NASDAQ:KOOL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AHoldHoldHold
Consensus Rating Score: N/A2.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Cesca Therapeutics (NASDAQ:KOOL) Consensus Price Target History

Price Target History for Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics (NASDAQ:KOOL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Maxim GroupReiterated RatingHoldLowView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Cesca Therapeutics (NASDAQ:KOOL) Earnings History and Estimates Chart

Earnings by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics (NASDAQ KOOL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/18/2018        
5/14/2018Q1 2018($0.27)$1.87 millionViewListenView Earnings Details
3/22/2018Q2 2018$0.01$2.94 millionViewN/AView Earnings Details
11/14/2017Q1 2018($0.24)$3.07 millionViewN/AView Earnings Details
9/19/2017Q4 2017($0.01)$3.50 millionViewN/AView Earnings Details
5/11/2017Q3 2017($0.21)$3.25 millionViewN/AView Earnings Details
2/13/2017Q2 2017($0.35)$4.01 millionViewN/AView Earnings Details
11/17/2016Q1 2017($0.34)$3.77 millionViewN/AView Earnings Details
9/20/2016Q4 2016($1.01)$2.98 millionViewN/AView Earnings Details
5/13/2016Q3 2016($1.42)$2.83 millionViewN/AView Earnings Details
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details
9/17/2015Q415($0.11)($0.06)$4.08 million$3.70 millionViewListenView Earnings Details
6/23/2015Q315($0.08)($0.12)$4.69 million$4.04 millionViewListenView Earnings Details
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details
9/29/2014Q4 2014($1.60)$3.84 millionViewN/AView Earnings Details
5/15/2014Q3 2014($0.05)($0.07)$4.04 millionViewN/AView Earnings Details
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details
11/14/2013Q1($0.14)$3.64 millionViewListenView Earnings Details
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/14/2013Q3 2013($1.40)$4.89 millionViewN/AView Earnings Details
2/12/2013Q2 2013($0.60)ViewN/AView Earnings Details
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details
9/20/2012Q4 2012($0.90)ViewN/AView Earnings Details
5/10/2012Q3 2012($2.14)ViewN/AView Earnings Details
2/9/2012Q2 2012($1.56)ViewN/AView Earnings Details
11/10/2011Q1 2012($1.48)ViewN/AView Earnings Details
9/12/2011Q4 2011($1.42)ViewN/AView Earnings Details
5/5/2011Q3 2011($1.14)ViewN/AView Earnings Details
2/10/2011Q2 2011$0.20($0.68)ViewN/AView Earnings Details
9/14/2010Q4 2010($0.80)($0.24)ViewN/AView Earnings Details
5/6/2010Q3 2010($1.92)ViewN/AView Earnings Details
2/4/2010Q2 2010($1.60)($2.08)ViewN/AView Earnings Details
11/5/2009Q1 2010($3.12)ViewN/AView Earnings Details
9/9/2009Q4 2009($0.80)($1.44)ViewN/AView Earnings Details
5/6/2009Q3 2009($1.60)($1.52)ViewN/AView Earnings Details
2/4/2009Q2 2009($3.20)($1.84)ViewN/AView Earnings Details
9/9/2008Q4 2008($2.40)($3.52)ViewN/AView Earnings Details
5/7/2008Q3 2008($1.60)($3.84)ViewN/AView Earnings Details
2/6/2008Q2 2008($2.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cesca Therapeutics (NASDAQ:KOOL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cesca Therapeutics (NASDAQ KOOL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 2.41%
Insider Trading History for Cesca Therapeutics (NASDAQ:KOOL)
Institutional Ownership by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics (NASDAQ KOOL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2016(Hong Kong) Ltd BoyalifeMajor ShareholderBuy6,102,942$2.52$15,379,413.846,838,237View SEC Filing  
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.804,490,410View SEC Filing  
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.804,490,410View SEC Filing  
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.004,490,410View SEC Filing  
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.004,571,268View SEC Filing  
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.004,571,268View SEC Filing  
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.204,581,778View SEC Filing  
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28245,066View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cesca Therapeutics (NASDAQ KOOL) News Headlines

Source:
DateHeadline
Cesca Therapeutics raises $5.5 million in stock offeringCesca Therapeutics raises $5.5 million in stock offering
www.bizjournals.com - May 22 at 9:09 AM
Cesca Announces Closing of $5.5 Million Public OfferingCesca Announces Closing of $5.5 Million Public Offering
finance.yahoo.com - May 18 at 4:47 PM
Today’s Research Reports on Stocks to Watch: Abaxis, Inc. and Cesca TherapeuticsToday’s Research Reports on Stocks to Watch: Abaxis, Inc. and Cesca Therapeutics
finance.yahoo.com - May 17 at 9:29 AM
Cesca Therapeutics (KOOL) Prices $5.5 Million Public Offering of Common Stock, WarrantsCesca Therapeutics (KOOL) Prices $5.5 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - May 16 at 4:39 PM
Cesca Prices $5.5 Million Public OfferingCesca Prices $5.5 Million Public Offering
feeds.benzinga.com - May 16 at 12:55 PM
Cesca Therapeutics Inc. (KOOL) Q1 2018 Results - Earnings Call TranscriptCesca Therapeutics Inc. (KOOL) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:47 AM
Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate UpdateCesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 4:39 PM
Cesca Therapeutics (KOOL) Posts Quarterly  Earnings ResultsCesca Therapeutics (KOOL) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 14 at 10:18 AM
Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14
finance.yahoo.com - May 9 at 9:20 AM
Cesca Therapeutics Inc. Presents New Data on its Proprietary X-Series™ Cellular Processing SystemsCesca Therapeutics Inc. Presents New Data on its Proprietary X-Series™ Cellular Processing Systems
feeds.benzinga.com - May 4 at 5:32 PM
Cesca Therapeutics (KOOL) Lifted to Hold at ValuEngineCesca Therapeutics (KOOL) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 11:51 PM
Cesca Therapeutics (KOOL) Set to Announce Quarterly Earnings on WednesdayCesca Therapeutics (KOOL) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:50 AM
Cesca Therapeutics (KOOL) and H2O Innovation (HEOFF) Critical ContrastCesca Therapeutics (KOOL) and H2O Innovation (HEOFF) Critical Contrast
www.americanbankingnews.com - April 29 at 7:55 AM
Comparing Cesca Therapeutics (KOOL) and H2O Innovation (HEOFF)Comparing Cesca Therapeutics (KOOL) and H2O Innovation (HEOFF)
www.americanbankingnews.com - April 27 at 8:52 AM
Contrasting Cesca Therapeutics (KOOL) & H2O Innovation (HEOFF)Contrasting Cesca Therapeutics (KOOL) & H2O Innovation (HEOFF)
www.americanbankingnews.com - April 26 at 12:08 PM
Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy ConferencesCesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
finance.yahoo.com - April 25 at 9:21 AM
Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series™ Products That Provide Automated, Closed System Cellular ProcessingCesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series™ Products That Provide Automated, Closed System Cellular Processing
finance.yahoo.com - April 24 at 4:49 PM
Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina LinebergerCesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger
www.nasdaq.com - April 24 at 9:15 AM
Cesca Therapeutics (KOOL) Raised to Hold at ValuEngineCesca Therapeutics (KOOL) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 19 at 2:58 PM
Has Cesca Therapeutics Inc (NASDAQ:KOOL) Improved Earnings Growth In Recent Times?Has Cesca Therapeutics Inc (NASDAQ:KOOL) Improved Earnings Growth In Recent Times?
finance.yahoo.com - April 17 at 5:02 PM
Cesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series™ Products That Provide Automated, Closed System Cellular ProcessingCesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series™ Products That Provide Automated, Closed System Cellular Processing
finance.yahoo.com - April 17 at 9:39 AM
Critical Analysis: H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)Critical Analysis: H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 16 at 7:41 PM
ValuEngine Lowers Cesca Therapeutics (KOOL) to SellValuEngine Lowers Cesca Therapeutics (KOOL) to Sell
www.americanbankingnews.com - April 16 at 7:35 PM
Head to Head Analysis: H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)Head to Head Analysis: H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 12 at 9:51 AM
Cesca Therapeutics (KOOL) vs. H2O Innovation (HEOFF) Critical SurveyCesca Therapeutics (KOOL) vs. H2O Innovation (HEOFF) Critical Survey
www.americanbankingnews.com - April 12 at 5:23 AM
Cesca Therapeutics (KOOL) & H2O Innovation (HEOFF) Head-To-Head SurveyCesca Therapeutics (KOOL) & H2O Innovation (HEOFF) Head-To-Head Survey
www.americanbankingnews.com - April 9 at 7:14 AM
Analyzing H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)Analyzing H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 7 at 11:16 AM
Reviewing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)Reviewing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 3 at 9:55 AM
Cesca Therapeutics (KOOL) Says Two Abstracts Accepted for Poster Presentation at ISCTCesca Therapeutics (KOOL) Says Two Abstracts Accepted for Poster Presentation at ISCT
www.streetinsider.com - April 3 at 9:35 AM
Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research MarketCesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market
finance.yahoo.com - April 3 at 9:35 AM
Comparing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)Comparing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 1 at 9:19 AM
Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual MeetingCesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting
finance.yahoo.com - March 28 at 9:33 AM
Cesca raising $1.4 million in direct offering of stockCesca raising $1.4 million in direct offering of stock
finance.yahoo.com - March 27 at 9:43 AM
Cesca inks direct placement of stock and warrants; shares down 17%Cesca inks direct placement of stock and warrants; shares down 17%
seekingalpha.com - March 26 at 4:28 PM
Cesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017, and Provides Corporate UpdateCesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017, and Provides Corporate Update
finance.yahoo.com - March 22 at 4:35 PM
Cesca Therapeutics (KOOL) Expands CAR-TXpress IP Portfolio with Filing of New Patent Covering Cell Activation & TransductionCesca Therapeutics (KOOL) Expands CAR-TXpress IP Portfolio with Filing of New Patent Covering Cell Activation & Transduction
www.streetinsider.com - March 19 at 9:29 AM
Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio with Filing of New Patent Covering Cell Activation & TransductionCesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio with Filing of New Patent Covering Cell Activation & Transduction
finance.yahoo.com - March 19 at 9:29 AM
Contrasting Cesca Therapeutics (KOOL) and Kadmon (KDMN)Contrasting Cesca Therapeutics (KOOL) and Kadmon (KDMN)
www.americanbankingnews.com - March 16 at 7:24 PM
Cesca Therapeutics (KOOL) Scheduled to Post Earnings on ThursdayCesca Therapeutics (KOOL) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 16 at 10:02 AM
Cesca Flat on ExpansionCesca Flat on Expansion
www.baystreet.ca - March 15 at 9:10 AM
Cesca Therapeutics to Announce Financial Results for the Transition Period From July 1, 2017 to December 31, 2017 on March 22Cesca Therapeutics to Announce Financial Results for the Transition Period From July 1, 2017 to December 31, 2017 on March 22
finance.yahoo.com - March 15 at 9:10 AM
Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) ServicesCesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services
finance.yahoo.com - March 14 at 10:16 AM
Cesca Therapeutics Inc. to Present at BIO-Europe Spring® 2018Cesca Therapeutics Inc. to Present at BIO-Europe Spring® 2018
finance.yahoo.com - March 6 at 9:10 AM
Comparing Cesca Therapeutics (KOOL) and Cardiome Pharma (CRME)Comparing Cesca Therapeutics (KOOL) and Cardiome Pharma (CRME)
www.americanbankingnews.com - March 4 at 3:20 PM
Analyzing Kadmon (KDMN) and Cesca Therapeutics (KOOL)Analyzing Kadmon (KDMN) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - February 28 at 1:30 AM
Cesca Therapeutics Inc. Announces Commercial Launch of AXP® II System for Advanced Cord Blood ProcessingCesca Therapeutics Inc. Announces Commercial Launch of AXP® II System for Advanced Cord Blood Processing
finance.yahoo.com - February 26 at 9:11 AM
Comparing Kadmon (KDMN) and Cesca Therapeutics (KOOL)Comparing Kadmon (KDMN) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - February 26 at 1:34 AM
Cesca Therapeutics Inc (NASDAQ:KOOL) And The Healthcare Industry Prospect For 2018Cesca Therapeutics Inc (NASDAQ:KOOL) And The Healthcare Industry Prospect For 2018
finance.yahoo.com - February 9 at 5:08 PM
Cesca Therapeutics Inc. to Present at the BIO CEO & Investor Conference on Monday, February 12, 2018Cesca Therapeutics Inc. to Present at the BIO CEO & Investor Conference on Monday, February 12, 2018
finance.yahoo.com - February 5 at 9:13 AM
Cesca Therapeutics (KOOL) versus Vitae Pharmaceuticals (VTAE) Critical SurveyCesca Therapeutics (KOOL) versus Vitae Pharmaceuticals (VTAE) Critical Survey
www.americanbankingnews.com - January 17 at 11:40 AM

SEC Filings

Cesca Therapeutics (NASDAQ:KOOL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cesca Therapeutics (NASDAQ:KOOL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cesca Therapeutics (NASDAQ KOOL) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.